TG4010 MUC-1 Targeted Immunotherapy

Quoix E, Limacher JM.
Current Respiratory Care Reports, 2014; 3 (1): 19-25

Limacher JM, Spring-Giusti C, Bellon N, Ancian P, Rooke R, Bonnefoy JY.
Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer.

De Meyer M, Farine I, Pichon C, Rooke R, Slos P.
Preclinical evaluation of MVA-MUC1-IL2 in combination with chemotherapy in murine models.
Journal for Immunotherapy of Cancer, 2013; 1 (Suppl 1)

Limacher JM, Quoix E.
TG4010: A therapeutic vaccine against MUC1 expressing tumors.
Oncoimmunology, 2012; 1(5): 791-792

A Phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
Cancer Immunology Immunotherapy, 2011; 60 (2): 261-271

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
Lancet Oncology, 2011; 12 (12): 1125-1133

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
Investigational New Drugs, 2009; 27: 379-386

Acres B.
Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Journal of B.U.ON., 2007; 12: S71-75

A phase II study of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer.
Journal of Thoracic Oncology, 2008; 3: 735-744
Acres B and Limacher JM.
MUC1 as a target antigen for cancer immunotherapy
Expert Review of Vaccines (2005), 4, 493-502

Phase I Immunotherapy With a Modified Vaccinia Virus (MVA) Expressing Human Muc1 as Antigen-Specific Immunotherapy in Patients With Muc1-Positive Advanced Cancer.